Does UnitedHealthcare Cover Jatenzo?

What Is Jatenzo and Why Does It Require Prior Authorization?

Jatenzo is the brand name for oral testosterone undecanoate 158 mg, 198 mg, and 237 mg soft-gelatin capsules. The FDA approved it in March 2019 specifically for adult men with primary or hypogonadotropic hypogonadism. Unlike topical gels or intramuscular injections, Jatenzo is absorbed through intestinal lymphatics, which reduces first-pass hepatic metabolism 1.

Because the list price runs close to $900 per month and cheaper testosterone formulations exist, UnitedHealthcare classifies Jatenzo as a non-preferred brand. That classification triggers automatic prior authorization review on virtually every commercial plan. Prior authorization exists because plans must verify that a clinically appropriate, lower-cost alternative has been considered before paying for the more expensive option.

The key Swerdloff et al. trial (J Clin Endocrinol Metab 2020, N=166) demonstrated that twice-daily Jatenzo titrated to 237 mg brought 87% of men into the normal total testosterone range (300, 1 to 000 ng/dL) at steady state 2. That efficacy data supports medical necessity arguments during PA review, but UHC still requires the plan's specific documentation checklist before approving payment.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness" and specifies two separate early-morning testosterone measurements below 300 ng/dL as a prerequisite for testosterone therapy 3. UHC's PA criteria mirror this language almost exactly.

Which UnitedHealthcare Plans Cover Jatenzo?

Most UHC commercial plans place Jatenzo on their formulary. Coverage looks different across plan types, so confirming your specific benefit document matters.

Commercial PPO and HMO plans. Jatenzo appears on the UHC Choice Plus, Manage, and Select formularies at Tier 3. Out-of-pocket costs in the deductible phase can equal the full negotiated rate, which is typically lower than the $900 list price but still substantial 4.

UHC Medicare Advantage (Part D). Medicare Part D plans are subject to non-interference rules, and Jatenzo's placement varies by plan year and region. Check the plan's Annual Notice of Change for the current tier. Because Jatenzo holds a protected-class designation as a hormone, some Part D plans cover it at Tier 2 or 3 without step therapy.

UHC Medicaid (Community Plan). Medicaid formulary decisions are state-administered. Jatenzo coverage is inconsistent; many state Medicaid programs exclude brand-name testosterone products when generic testosterone cypionate is available at significantly lower cost 5.

Employer self-funded (ASO) plans. Employers who self-fund their benefits can customize formulary tiers. Some large employers exclude Jatenzo entirely. Others cover it at Tier 2 if the employer negotiated a performance-based contract with UHC. Always confirm with the employer's HR benefits team, not just the UHC member portal.

The FDA's Orange Book lists no therapeutically equivalent generic for Jatenzo (oral testosterone undecanoate, NDA 210236), which is why it cannot be substituted at the pharmacy counter the way a generic can replace a brand 6.

UnitedHealthcare Prior Authorization Criteria for Jatenzo

Prior authorization for Jatenzo on UHC plans generally requires all of the following.

Diagnosis confirmation. The prescriber must document primary hypogonadism (failure of the testes themselves, e.g., Klinefelter syndrome, orchidectomy, chemotherapy) or hypogonadotropic hypogonadism (hypothalamic or pituitary failure). A low testosterone reading alone, without a coded diagnosis of E29.1 (testicular hypofunction) or a related ICD-10 code, will result in an automatic denial.

Two low testosterone lab values. Both draws must occur before 10 a.m. after an overnight fast. Total testosterone must be below 300 ng/dL on both occasions, drawn at least one week apart. A single low value is insufficient per Endocrine Society guidelines 3 and insufficient per UHC's medical policy.

Step therapy (most plans). UHC requires a documented trial of at least one preferred testosterone product before approving Jatenzo. Preferred alternatives on most UHC formularies include testosterone cypionate injection (Tier 1 generic) and testosterone gel 1% or 1.62% (Tier 2). A step failure means the patient either could not tolerate the alternative, had inadequate response after an adequate trial period (typically 90 days), or has a documented medical contraindication to the preferred product 7.

Prescriber specialty. Some UHC plans require the ordering clinician to be a urologist, endocrinologist, or reproductive endocrinologist. A primary care prescription may trigger additional documentation requests. Board certification or specialty credentials of the signing provider can be uploaded as supporting documentation.

Prior authorization approval period. UHC typically grants Jatenzo PA approvals for 12 months. Renewals require re-documentation of ongoing symptomatic benefit and continued testosterone monitoring. If serum testosterone has normalized and symptoms have resolved, the PA is renewed with updated labs showing therapeutic levels (300, 1 to 000 ng/dL) 2.

Step Therapy Requirements: What Counts as a Failed Trial?

Step therapy is the most common reason Jatenzo prior authorizations are denied on the first submission. UHC requires documentation that a step therapy alternative was genuinely attempted, not merely prescribed.

A documented failed trial means pharmacy records show the patient dispensed the preferred product for the required duration (usually 60 to 90 days), and the prescriber has written a clinical note describing either inadequate therapeutic response (testosterone levels below 300 ng/dL despite adherence) or a specific adverse effect. Common documented failures include contact transfer dermatitis from gels (relevant particularly in households with children or pregnant partners), injection-site hematoma or patient inability to self-inject, or erythrocytosis during cypionate therapy requiring dose reduction to sub-therapeutic levels 8.

Some state laws now limit step therapy mandates. As of 2024, over 30 U.S. states have enacted step therapy reform legislation that requires exceptions when a prescriber documents clinical reasons why the preferred product is contraindicated or inappropriate 9. If your state has such a law, your physician can invoke a step therapy override by submitting a letter of medical necessity that cites the specific statutory language.

How to Submit a Jatenzo Prior Authorization to UHC

The prescribing physician or their office submits the PA through one of three channels: the UHC provider portal (availity.com), a fax to the UHC pharmacy benefit PA line, or through the electronic prior authorization (ePA) workflow embedded in the EHR if the practice uses a compatible system.

The submission package should include:

• The completed UHC testosterone replacement therapy PA form
• Two morning testosterone lab reports with collection timestamps
• Office notes documenting symptom burden (fatigue, libido changes, loss of muscle mass) tied to the ICD-10 diagnosis code
• Pharmacy records showing dispensing history for the step therapy product
• A letter of medical necessity from the prescriber explaining why Jatenzo specifically is appropriate for this patient

Processing time for standard PA requests is 3 business days for commercial plans. Urgent PA requests (when a clinical delay would seriously jeopardize the patient's health) must be resolved within 72 hours, and emergency situations allow 24-hour turnaround per UHC's utilization management policy 10.

What Formulary Tier Is Jatenzo on UnitedHealthcare?

On most UHC commercial formularies, Jatenzo sits at Tier 3 (non-preferred brand). Tier 3 typically means the highest fixed copay within the brand category, often $60, $120 for a 30-day supply after the deductible is met. During the deductible phase, the member pays the full negotiated rate, which UHC typically negotiates to $600, $750 per month for Jatenzo, depending on the pharmacy network 4.

The table below summarizes how Jatenzo's tier compares with other testosterone products on a representative UHC commercial formulary.

| Product | Tier | PA Required | Step Required | |---|---|---|---| | Testosterone cypionate injection (generic) | 1 | No | No | | Testosterone gel 1% (generic) | 2 | No | No | | AndroGel 1.62% (brand) | 3 | Yes | After Tier 1/2 | | Jatenzo 237 mg (brand) | 3 | Yes | After Tier 1/2 | | Natesto nasal gel (brand) | 3 | Yes | After Tier 1/2 |

Tier placement can change annually with the January 1 formulary update. Members receive a notice of formulary change 60 days before the effective date if their current medication moves to a higher tier.

How to Appeal a UnitedHealthcare Denial of Jatenzo

UHC operates a two-level internal appeal process followed by an external independent review if both internal levels fail.

Level 1 Internal Appeal. File within 180 days of receiving the denial letter. The appeal goes to a UHC medical director who was not involved in the original decision. Include all documents from the original PA plus any new clinical evidence. The American Urological Association's 2018 guideline on testosterone deficiency states that "clinicians should offer testosterone therapy to men with testosterone deficiency who have symptoms of testosterone deficiency" and specifies oral testosterone as an appropriate route 11. Citing a named guideline from a specialty society carries weight in internal reviews. Level 1 decisions are due within 30 days for non-urgent requests or 72 hours for urgent ones.

Level 2 Internal Appeal. If Level 1 fails, request a Level 2 review. At this stage, UHC often allows a peer-to-peer call between the prescribing physician and the UHC medical director. The peer-to-peer is arguably the single highest-yield step in the entire process. Physicians should prepare for this call by reviewing the specific UHC medical policy number, the patient's lab trends, the step therapy failure documentation, and the relevant guideline citations 12.

External IRO (Independent Review Organization). If both internal levels fail, the member has the right to an external review by a state-certified IRO. The IRO is staffed by clinicians with no financial relationship to UHC. They apply an independent medical necessity standard. Approval rates at IRO review for hormone replacement denials run meaningfully higher than the internal appeal approval rate, though published figures vary by state 9.

State Insurance Commissioner complaint. Filing a complaint with the state insurance commissioner while the appeal is pending does not accelerate the process legally, but it does create a regulatory record. Some states require insurers to respond to commissioner inquiries within 15 days.

Manufacturer Savings Card and Patient Assistance

Clarus Therapeutics (the Jatenzo manufacturer) has historically offered a savings card that can reduce the out-of-pocket cost to as low as $0 per fill for eligible commercially insured patients. The card cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or any federal insurance program because of federal anti-kickback rules 13.

For commercially insured patients on UHC, the savings card may stack with the insurance benefit to offset the Tier 3 copay. In practice, the card pays the difference between what UHC pays and the patient's cost-share, up to the card's annual maximum. Contact Clarus or the Jatenzo website directly for current card terms, as these change annually.

Patients who have exhausted appeals and cannot afford Jatenzo may qualify for the manufacturer's patient assistance program (PAP). PAP eligibility typically requires annual household income below 400 to 600% of the federal poverty level and absence of other prescription coverage. The prescribing office submits the PAP application on the patient's behalf 14.

Clinical Monitoring Requirements During Jatenzo Therapy

UHC PA renewals and the Endocrine Society guideline both require ongoing monitoring to justify continued coverage. The Swerdloff et al. trial used serum total testosterone measured 6 hours post-dose as the primary pharmacokinetic endpoint, with titration allowed at week 3 based on that measurement 2.

Standard monitoring for patients on Jatenzo includes:

• Serum total testosterone (drawn 6 hours post-dose) at 3 to 4 weeks after initiation and after any dose change
• Hematocrit at baseline and every 3 to 6 months (the Endocrine Society recommends withholding therapy if hematocrit exceeds 54%) 3
• PSA at baseline for men over 40, then at 3 to 6 months and annually
• Blood pressure monitoring at each visit, given Jatenzo's FDA boxed warning for hypertension (mean systolic increase of 3.9 mmHg observed in clinical trials) 1
• Lipid panel at baseline and at 6 months (oral testosterone undecanoate may affect HDL cholesterol)

Keeping these lab records current makes PA renewals straightforward and provides ammunition for any future appeal if UHC attempts to discontinue coverage.

Jatenzo vs. Other Testosterone Options on UHC Formulary

Choosing Jatenzo over a preferred formulary product has real cost implications, and UHC's step therapy requirement reflects that reality. Testosterone cypionate 200 mg/mL injection is available at Tier 1 for as little as $10, $25 per month at major pharmacy chains, making it the most cost-effective option for most patients 15.

The clinical case for Jatenzo centers on specific patient populations: men who refuse or cannot safely self-inject, men with occupational or household contraindications to topical transfer (e.g., living with young children or a pregnant partner), men with documented skin reactions to transdermal products, and men who prefer a lymphatic absorption mechanism that avoids hepatic first-pass metabolism. The FDA's prescribing information notes that Jatenzo should be taken with food to optimize lymphatic absorption, with the capsules swallowed whole (not chewed) 1.

JAMA Internal Medicine published data showing that adherence to testosterone therapy is significantly higher with oral formulations compared with weekly injections in men with needle aversion, which is a clinically meaningful differentiator when drafting a letter of medical necessity 16.

Working with a Telehealth Provider to Manage UHC Coverage

Telehealth TRT platforms that are familiar with UHC's utilization management process can reduce the time from prescription to coverage decision by ensuring the PA packet is complete on first submission. Incomplete packets are the leading cause of administrative denials, and those denials reset the processing clock.

A well-organized first-submission PA for Jatenzo should take no more than 10, 15 business days to resolve through UHC's standard commercial pathway. If UHC requests additional information (ADI), the provider has 10 business days to respond before the request lapses and requires resubmission. Telehealth providers who use integrated EHR-to-payer PA automation tools can monitor ADI requests in real time and respond within 24 to 48 hours, keeping the timeline on track.

The Endocrine Society's 2020 position statement on telehealth and endocrine care supports remote testosterone management when appropriate laboratory monitoring is in place, noting that testosterone replacement therapy is "well-suited to telemedicine follow-up given the availability of home-collected dried blood spot and serum testosterone testing" 17.